New pill shows promise for shedding pounds in obesity trial

NCT ID NCT06703021

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tested an experimental drug called aleniglipron (GSBR-1290) to help people with obesity or overweight lose weight. About 85 adults took either the drug or a placebo for 44 weeks, along with diet and exercise. The main goals were to check safety and side effects, and to see how the drug works in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ACCESS II Research Site

    Glendale, California, 91206, United States

  • ACCESS II Research Site

    Montclair, California, 91763, United States

  • ACCESS II Research Site

    Valparaiso, Indiana, 46383, United States

  • ACCESS II Research Site

    West Des Moines, Iowa, 50265, United States

  • ACCESS II Research Site

    Medford, Oregon, 97504, United States

  • ACCESS II Research Site

    East Greenwich, Rhode Island, 02818, United States

  • ACCESS II Research Site

    North Charleston, South Carolina, 29405, United States

  • ACCESS II Research Site

    Dallas, Texas, 75042, United States

  • ACCESS II Research Site

    San Antonio, Texas, 78240, United States

  • ACCESS II Research Site

    West Jordan, Utah, 84088, United States

Conditions

Explore the condition pages connected to this study.